Author Archives: William Looney

Breaching the Great Wall: Major Pharma Changes Proposed in China

With a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. Dr. Wang Chenguang, Dean of Tsinghua Law School Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a […]
Posted in compliance, Emerging Markets, Global, IP, R&D, Regulatory | Tagged , , , , , , , , , , | 3 Comments

Strange Bedfellows No More: EMA Moves Closer to Payers

That strict red line between regulatory authorization and market reimbursement is blurring pink – at least in Europe.  At a Drug Information Association [DIA] session earlier this week, European Medicines Agency [EMA] Senior Medical Officer Hans-Georg Eichler confirmed that the agency was finally moving to test the feasibility of a new, “holistic” approach to obtaining […]
Posted in Europe, FDA, Regulatory | Tagged , , , | Leave a comment

Medicines Patent Pool: Industry's Toe Still in the Water

At a time when Big Pharma is struggling with new business models geared to the demands of a changing marketplace, the Medicines Patent Pool (MPP) is offering a way forward through voluntary licensing and patent deals that it insists will deliver what the drug majors say they want: more innovation; better market access; and the […]
Posted in healthcare, IP | Tagged , , , , | Leave a comment

The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling

Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting.  Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, pricing, Strategy | Tagged , , , , , , , , | 6 Comments

Is There a Global Policy Gap on Cancer?

Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day.  Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the […]
Posted in Global | Tagged , , , | Leave a comment
  • Categories

  • Meta